Genentech’s Post

Although Macular Telangiectasia, a hitherto untreatable cause of central vision loss, is uncommon, retina specialists see several MacTel patients every week, slowly going blind. Hopefully, this gets through the FDA quickly and is available to patients that we've been watching helplessly slowly go blind! https://lnkd.in/eNZ7TiBe #preventableblindness #maculartelangiectasia #mactel

Sight Sciences’ TearCare leads to long term improvement in dry eye disease: The data is from Sight Science’s SAHARA trial – a study evaluating #TearCare in patients previously treated with Allergan (AbbVie’s) Restasis eyedrops (cyclosporine ophthalmic emulsion). TearCare, which is already cleared by the US Food and Drug Administration (FDA), uses localised heat therapy via non-surgically affixed electrothermal devices. Restasis, meanwhile, is the current standard treatment for dry eye disease. https://lnkd.in/g2g2txhC #RegulatoryAffairs #Regulatoryscience

Well-indicated medical indications and procedures are always necessary to have an adequate risk / benefit…

“Nobody disputes the value of glucocorticoids, and while most clinicians recognize the damage they cause to patients, they don’t recognize the damage they do to clinical research.” - Andreas Reiff, MD Read on in our latest In Conversation piece to hear more from Dr Reiff on why the best steroid is no steroid: https://hubs.li/Q02ttbrn0 #SteroidToxicity #SteritasGTI #ClinicalResearch #ClinicalTrials #PrescriptionDrugs

In 1921, surgeon Frederick Banting and medical student Charles Best first discovered insulin from a canine pancreas experiment, which transformed diabetes treatment. In 2016, the FDA approved the artificial pancreas, freeing people with diabetes from daily injections. In honor of World Diabetes Day, we're reflecting on the long history of insulin discovery and development, a journey marked with serendipity, collaboration, and controversy. Read more here: https://ow.ly/UwP650Q5c4Z

Have you seen the news about the latest Ozempic/Wegovy injury? According to a new study by Mass General Brigham researchers, patients taking Ozempic and Wegovy face a greater risk of a stroke of the optic nerve...a rare condition called NAION (Nonarteritic anterior ischemic optic neuropathy). NAION is a rare condition that afflicts 2 to 10 out of 100,000 people. Like a brain stroke, the condition occurs from reduced blood flow to the optic nerve, which can damage tissue. It is the second most common cause of blindness from optic nerve damage, trailing only glaucoma. Will we see this added to the current list of injuries on the Ozempic/Wegovy MDL? https://loom.ly/pjhCx0U #Ozempic #Sideeffects #MDL

SELUTION SLR is now being studied in 4 IDE trials! After SELUTION4SFA SELUTION4BTK , SELUTION4ISR , the very first patient with denovo coronay disease has been enrolled in #SELUTION4DeNovo study at Mount Sinai by Dr Samin Sharma. Selution4Denovo Study PI: Dr Ron Waksman more information about the study? see the comment section

Message me if you would like to discuss the novel therapy for Cardio-Renal Syndrome!

Most medical professionals are not aware that patients with breast implants may be experiencing systemic health complications (Breast Implant Illness), autoimmune diseases, or cancer that is caused by breast implants. In October 2022, the FDA announced various cancers that are caused by breast implants including: 👉 BIA-ALCL Anaplastic Large Cell Lymphoma 👉 BIA-SCC Breast Implant Associated Squamous Cell Carcinoma 👉 B-Cell Lymphomas 👉 T-Cell Lymphomas 👉 Melanoma The FDA has failed to alert the medical community with a DHCP healthcare provider letter to convey this critical information. Read how this is affecting patients and impeding timely diagnosis of disease. https://lnkd.in/gjRAM6pY

🤍 Restore Medical secured FDA breakthrough device designation for its ContraBand system to treat left ventricle failure. The device is claimed to be the first transcatheter pulmonary artery banding system in the world to improve the patient’s quality of life. 💬 Restore Medical, led by CEO Gilad Marom, stated: “This designation marks a significant milestone in the company’s mission towards the improvement of cardiac care for heart failure patients as it highlights the potential of the ContraBand device to address critical unmet needs in the treatment of HFrEF patients.” 👉 Learn more: https://lnkd.in/dXfN23Mc 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dvz_fgir #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #HealthTech #Surgeons #GuidedSolutions